Talk Evidence Will semaglutide buck the trend of other weight loss drugs?
Helen Macdonald, BMJ's publication ethics and content integrity editor, and Juan Franco, editor of BMJ EBM are back with another episode of Talk Evidence.
This month, we'll be focussing on semaglutide, for managing obesity. Interviews with James Cave, editor-in-chief of Drug and Therapeutic Bulletin, and Lene Bull Christiansen, who has personal and professional experience with obesity, are featured. They discuss the history of drug therapies for obesity, and wonder if the wonderdrug semaglutide will turn out to be as disappointing. They discuss the evidence base for use of semaglutide, its effectiveness in weight management, and the broader societal issues surrounding obesity treatment.
Next, the hosts delve into undisclosed financial conflicts of interest in the DSM-5, focusing on a study led by Lisa Cosgrove and colleagues. The study reveals significant ties between DSM-5 authors and pharmaceutical companies, raising concerns about industry influence on psychiatric diagnosis and treatment recommendations.
The episode concludes with a discussion on survival rates after in-hospital cardiac arrest, based on a study using data from the Get With The Guidelines Resuscitation database. The hosts analyze the implications of the study findings for clinical practice and advanced care planning.
- Interview with James Cave: 00:03:15
- Interview with Lene Bull Christiansen: 00:11:07
- Interview with Lisa Cosgrove: 00:25:07
- Survival after in-hospital cardiac arrest: 00:31:25
Reading list
NEJM - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
DTB - Semaglutide: a new drug for the treatment of obesity
BMJ - Undisclosed financial conflicts of interest in DSM-5-TR: cross sectional analysis